TGA-approved coronavirus-killing labelling out in force
A surface disinfectant produced by Whiteley Corporation is reported to be the first product in Australia to carry the new Australian Therapeutic Goods Administration (TGA)-approved label claim against the SARS-CoV-2 (COVID-19) virus.
The TGA confirmed that Viraclean “Kills Coronavirus, SARS-CoV-2 (COVID-19)”, which has been added to the product’s label.
The new label comes following new amendments to the TGA guidelines under Therapeutic Goods Order 104, which allow listed disinfectants to make validated claims to kill the SARS-CoV-2 (COVID-19) virus on surfaces.
Viraclean is a hospital-grade disinfectant intended for use on a wide range of hospital surfaces that may be contaminated. The product can help the healthcare sector to protect hospital patients and staff from the risk of SARS-CoV-2 (COVID-19) virus cross-infection via inanimate high-touch objects and surfaces.
Chairman of Whiteley Corporation Dr Greg Whiteley said the new label claim will provide the Australian and New Zealand healthcare community with certainty around cleaning and disinfecting of healthcare surfaces and non-critical medical devices.
“This new label claim for Viraclean against the virus responsible for the current pandemic will add to certainty around the level of hygiene in hospitals, particularly in intensive care units, emergency departments and a range of other clinical, medical and dental applications,” Dr Whiteley said.
The COVID-19 coronavirus has the capacity to survive on hard and relatively soft surfaces for a prolonged period of time, meaning that cleaning and disinfecting those surfaces is incredibly important to limit the spread of the virus.
Dr Whiteley explained that hospital surfaces around a patient who is infected with this virus will be contaminated by the patient shedding the virus.
“The testing against coronavirus in the case of this SARS-CoV-2 (COVID-19) relies on a number of surrogate viruses. This is important because using a surrogate protects the laboratory staff but allows a scientifically accurate representation of the disinfectant performance against all of the coronaviruses including SARS-CoV-2 (COVID-19) virus.
“This approach allows the TGA to manage the regulatory aspects of both the approval and also market performance to ensure public health standards are maintained.”
Could UV light protect against hospital infections?
Researchers are working on a new type of ultraviolet light that could be effective for reducing...
Alfred Health trials eye-tracking tech to assess brain function
The Alfred hospital has commenced clinical trials with BrainEye to screen for neurological...
Australian regions with high cardiac arrest rates and low CPR: study
Australia has about 26,000 out-of-hospital cardiac arrests annually, with only 12% of patients...
